317 related articles for article (PubMed ID: 28891241)
21. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
22. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab-Induced Colitis Treated by Infliximab.
Yanai S; Nakamura S; Matsumoto T
Clin Gastroenterol Hepatol; 2017 Apr; 15(4):e80-e81. PubMed ID: 27664866
[No Abstract] [Full Text] [Related]
24. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
Gambichler T; Stockfleth E; Susok L
J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
[TBL] [Abstract][Full Text] [Related]
26. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
[No Abstract] [Full Text] [Related]
27. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
28. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
29. Ipilimumab-induced colitis in patients with metastatic melanoma.
De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
[TBL] [Abstract][Full Text] [Related]
30. Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event.
Mangas C; Leoni-Parvex S; Spataro V
Cancer Immunol Immunother; 2020 Nov; 69(11):2409-2410. PubMed ID: 32964272
[No Abstract] [Full Text] [Related]
31. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
32. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
[No Abstract] [Full Text] [Related]
33. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
34. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
35. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
36. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
37. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
38. A Life-Threatening Cause of Colitis.
Jaswani TS; Grider DJ; Bern MJ
Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
[No Abstract] [Full Text] [Related]
39. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
[No Abstract] [Full Text] [Related]
40. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
